Page 916«..1020..915916917918..930940..»

COVID-19 Pandemic Impact on Global Stem Cell Therapy Market 2020-2024 | Technavio – Business Wire

Posted: August 26, 2020 at 8:00 pm

LONDON--(BUSINESS WIRE)--The stem cell therapy market is expected to register a CAGR of almost 7% during 2020-2024, as per the latest research report by Technavio. The report offers a detailed analysis of the impact of COVID-19 pandemic on the market in optimistic, probable, and pessimistic forecast scenarios.

Request for Technavios market report estimates including pre- and post-COVID-19 impact on stem cell therapy market. Download a Free Sample Report on the impact of COVID-19 pandemic analysis.

Due to the extensive spread of the virus across the globe, the Health Care Industry is anticipated to have Positive impact. The stem cell therapy market will showcase Neutral impact during 2020-2024.

Stem Cell Therapy Market 2020-2024: Segmentation

Stem Cell Therapy Market is segmented as below:

North America region will account for the highest incremental growth during the forecast period due to the high number of research facilities and government funding for innovative stem cell and regenerative medicine research.

With the surging growth of COVID-19 pandemic, the Health Care market is anticipated to have a Direct impact during the forecast period. View market snapshot before purchasing

Limited number of FDA-approved stem cell therapies has been an instrumental factor in influencing the growth of stem cell therapy market. Other market drivers include accelerated regulatory approval. Technavio offers custom research analysis on the crucial pointers to highlight the impact of COVID-19 on the market across the supply chain.

Key Considerations for Market Forecast:

Get more insights about the global trends impacting the future of stem cell therapy market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR43432

Stem Cell Therapy Market 2020-2024: Vendor Analysis

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Key players in the market have been launching several initiatives and introducing innovative products and services to cater to a larger target audience during the pandemic. Major market participants include Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original here:
COVID-19 Pandemic Impact on Global Stem Cell Therapy Market 2020-2024 | Technavio - Business Wire

Posted in Stem Cell Therapy | Comments Off on COVID-19 Pandemic Impact on Global Stem Cell Therapy Market 2020-2024 | Technavio – Business Wire

ProgenCell – Stem Cell Therapies announces new facilities – PR Web

Posted: August 26, 2020 at 8:00 pm

Our patients will have access to even more services and extraordinary specialists available at the medical tourism complex, in a convenient and strategic location.

SAN DIEGO (PRWEB) August 25, 2020

ProgenCell - Stem Cell Therapies is announcing the opening of its brand new Stem Cell Treatment Center to give international and local patients a more comprehensive medical treatment in a luxury and stress free environment. With this announcement, ProgenCell establishes its leadership in the field of regenerative medicine and medical tourism. ProgenCells New Clinic is part of the one of a kind all-in-house medical tourism complex: NewCity Medical Plaza.

A great deal of planning went into making this stem cell treatment right for the wide range of medical conditions we deal with, said Dr Jorge Gavino, president of ProgenCell Scientific Committee. Our patients will have access to even more services and extraordinary specialists available at the medical tourism complex, in a convenient and strategic location. Im excited to welcome patients at this new facility.

It has been a long journey. Time had given lot of experience since 2008, when the clinic was found, said Elias Bemaras, CEO. Stem cell therapy has evolved, has improved in many ways, getting better results, learning from long term treated patients. We understand the need for a new facility, more convenient for patients with equipment renovation, better distribution, and a better location. Although a high investment is required, we believe it is worth it because our patients will receive better service, easier logistics, more time with the doctor, better follow up, and that translates to 360 degrees patient satisfaction.

With this new facility, ProgenCell establishes its commitment to offer the most advanced technology in modern and comfortable facilities and in a fully licensed, government regulated and certified facility, overseen by an independent ethics and scientific committee.

About ProgenCell - Stem Cell TherapiesProgenCell - Stem Cell Therapies is a leading stem cell treatmentcenter that offers individualized stem cell therapies for patients with chronic-degenerative diseases with more than 10 years of experience. ProgenCell also provides assistance with lodging, traveling and logistics to provide a comprehensive and safe medical tourism experience.ProgenCell is now part of the Health System of NewCity Medical Plaza, a modern and innovative Medical Tourism Center in Tijuana, Mexico. NewCity Medical Plaza is a 30-story tower, with doctors offices, hospital, medical lab, imaging center, commercial plaza, gastronomic center and a 140-room five star hotel.

To learn more about ProgenCell new facilities or scheduling inquiries contact ProgenCell directly at 1 888 443 6235 or email info@progencell.com

Share article on social media or email:

Read the original:
ProgenCell - Stem Cell Therapies announces new facilities - PR Web

Posted in Stem Cell Therapy | Comments Off on ProgenCell – Stem Cell Therapies announces new facilities – PR Web

Animal Stem Cell Therapy Market 2020 | Global (North America, Europe, Middle East & Africa, Latin America and the Asia Pacific) Market Status and…

Posted: August 26, 2020 at 8:00 pm

Global Animal Stem Cell Therapy Market 2020-2025 Analysis &Forecast Report: By Region, Application, Type, Key Players Global (North America, Europe, Middle East & Africa, Latin America and the Asia Pacific) Forecast 2025.

Global Animal Stem Cell Therapy Market research report focuses on Current & Future Market Size, Price, Trends, Shares, Segment & Forecast 2020-2025 and gives in-depth analysis of past and future six years industryOpportunities,Sales, Revenue, consumption, and Market Growth Analysis.

Animal Stem Cell Therapy Research report gives a comprehensive analysis of present and future Opportunities toexplains the forthcoming interest in the market. Animal Stem Cell TherapyMarket report gives manufacturers, regional analysis, figure, segmented by End-users type and applications and the real procedure of entire Animal Stem Cell Therapy Marketplace. Worldwide Animal Stem Cell Therapyindustry 2011-2025 report shares data about key driving components, risks, and opportunities with its impact by Region.

Request For The Free Sample Copy Of Animal Stem Cell Therapy Market Report Which Provides Key Market Trends | Growth Forecast | Sale | Revenue | Manufactures @ https://www.eonmarketresearch.com/sample/49209

Key Players: Market Segmented By Prominent Players:

VETSTEM BIOPHARMA, MediVet Biologic, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

An up to date research report has been disclosed by Eon Market Research highlighting the title Global Animal Stem Cell Therapy Market Research Report 2020 which presents an outlook of modern marketplace growth as well as the predicted forecast along with Rate on Investment (ROI) collectively with developing CAGR close to XX% all through 2020-2025. The file studies Animal Stem Cell Therapy industry revenue in the global marketplace, especially in North the united states, China, Europe, Southeast Asia, Japan, and India, with production, consumption, revenue, import and export in those areas.

Segmentation by type:

DogsHorsesOthers

Segmentation by application:

Veterinary HospitalsResearch Organizations

Global Animal Stem Cell Therapy Market Analysis Covers The Following Points

Animal Stem Cell Therapy Industry Sales, Revenue, and Market Growth Analysis.

Region-wise market Size, SWOT,PEST,ROI(Return on Investment)Analysis.

Animal Stem Cell Therapy Industry Forecast (Industry Level, Product Type Level, Channel Level) 2020-2025.

Animal Stem Cell Therapy Industry Positioning Analysis and Animal Stem Cell Therapy Market Drivers and Opportunities.

Market Opportunities, market risk, market driving force.

Animal Stem Cell Therapy Marketing Channel Development Trend & Competitive landscape.

Animal Stem Cell Therapy Business Supply and demand, Pricing Strategy, Brand Strategy.

Buy This Premium Report:https://www.eonmarketresearch.com/buy/49209

Scope: Scope Of Animal Stem Cell Therapy Market:

This report basically covers Animal Stem Cell Therapy industry in North America, Europe, Middle East and Africa, Latin America and the Asia Pacific. This report isolates the Animal Stem Cell Therapy market based on competitive players, type, regions, and applications. At the start, the report covers the pinnacle Animal Stem Cell Therapy industry players from locales like the United States, EU, Japan, and China.

This report identifies the global Animal Stem Cell Therapy marketplace size in for the year 2011-2017, and forecast of the equal for the year 2025. It additionally highlights the ability to increase possibilities in the upcoming years, even as additionally reviewing the marketplace drivers, restraints, growth signs, challenges, market dynamics, aggressive landscape, and different key aspects with appreciation to worldwide domestic Animal Stem Cell Therapy marketplace.Global Animal Stem Cell Therapy Market gives a region-wise analysis like growth aspects, sales and revenue, Past, present and forecast trends, Analysis of emerging market sectors and development opportunities in {{ keyword }} will forecast market growth.

Global Animal Stem Cell TherapyMarketplace Segment by Regions, regional analysis covers:

Animal Stem Cell TherapyMarket in North America (Canada and Mexico).

Europe Animal Stem Cell TherapyMarket(Germany, France, UK, Russia and Italy).

Animal Stem Cell TherapyMarket in Asia-Pacific (China, Japan, Korea, India and South-east Asia).

Latin America Animal Stem Cell TherapyMarket, Middle and Africa.

Subsequent parts of the report, gives statistics which include market, product, price and channel capabilities with appreciate to the forefront Animal Stem Cell Therapy exhibit designs anticipated inside the midst of the take a look at time allotment from 2020 to 2025, Animal Stem Cell Therapy marketplace selling techniques, local and funding evaluation and sales analysis of Animal Stem Cell Therapy market put it up for sale sellers, measurable statistics functions of the Animal Stem Cell Therapy market and fundamental Animal Stem Cell Therapy business end nearby facts accumulating sources and reference vicinity.

Any Questions? Feel Free To Enquire Here. We will Put You On The Right Path: https://www.eonmarketresearch.com/enquiry/49209

Table Of Content OfGlobal Animal Stem Cell TherapyMarket:

To depict Animal Stem Cell Therapy Introduction, item scope, market diagram, showcase openings, Market hazard, advertise the main thrust;

To examine the best makers of Animal Stem Cell Therapy, with deals, income, and cost of Animal Stem Cell Therapy, in 2016 and 2017;

To show the focused circumstance among the best makers, with deals, income, and piece of the overall industry in 2016 and 2017;

To demonstrate the worldwide market in locales, with deals, income, and piece of the overall industry of Animal Stem Cell Therapy, for every district, from 2013 to 2018;

To investigate the market by nations, by type, by application, and by makers, with deals, income, and piece of the overall industry by entering nations in these areas;

To demonstrate the market by sort and application, with deals piece of the pie and development rate by type, application, from 2013 to 2018;

Animal Stem Cell Therapy showcase conjecture, by districts, sort, and application, with deals and income, from 2018 to 2023;

To depict Animal Stem Cell Therapy deals channel, wholesalers, brokers, merchants, Research Findings and Conclusion, reference section and information source.

*** Thanks for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. ***

About us:

EON Market Research(EMR) is a market research-based company that empowers data-driven companies. We provide accurate and well-informed market research reports, Real-Time with Real Application. Good research methodology proves to be effective and concise knowledge that uses complex decisions from day-to-day to day-to-day life to help us manage vision, intention and well-armed strategies. At EON Market Research, we are constantly striving for excellence in the techniques and consistency of research in our studies.

Contact Us:

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

Read the rest here:
Animal Stem Cell Therapy Market 2020 | Global (North America, Europe, Middle East & Africa, Latin America and the Asia Pacific) Market Status and...

Posted in Stem Cell Therapy | Comments Off on Animal Stem Cell Therapy Market 2020 | Global (North America, Europe, Middle East & Africa, Latin America and the Asia Pacific) Market Status and…

The Road To Scale: Challenges Facing the Implementation of Animal-Free Recombinant Proteins Into Stem Cell Supply Chains – Technology Networks

Posted: August 26, 2020 at 8:00 pm

Most industries today are under pressure to switch to more ethical and sustainable animal-free alternatives, and now the trend is coming to stem cell labs. As stem cell applications accelerate towards the clinic, novel drug discovery platforms are rapidly scaled, and new transformative stem cell-based technologies such as cultured meat arise, there is a drive to switch to animal-free cell culture media. This move is essential to facilitate future regulatory approval for advanced therapies, and enable pharma and biotech companies to ethically, reproducibly and cost-effectively scale stem cell-based innovations.Most stem cell scientists today use recombinant growth factor and cytokine proteins in their chemically-defined media to supply their cultures with the necessary biological signals required for maintenance of pluripotency, cell proliferation and differentiation into specific cell lineages. However, the fundamental biochemistry and manufacturing processes of these protein messengers can often be overlooked. But as scientists are trying to establish new animal-free systems to support the scale-up of their stem cell applications, the properties and challenges inherent in these proteins are becoming more prominent and frankly a headache for many.

Highlighted here are three key challenges facing pharma and biotech companies as they embark on the path to implementing animal-free systems, from the perspective of two protein scientists.1.Why batch consistency is kingAs stem cell therapies gear up to make the leap from bench to clinic and the promise of stem cell biology in drug discovery and other industrial applications is realized, more subtle and still largely inexplicable challenges in optimizing growth factor and cytokine supply chains for defined media are being identified why when you change from one supplier or even batch of a recombinant protein do stem cells need weaning onto that protein, or dont tolerate the change? Is this a fundamental lack of batch consistency across the supply chain or is there an underlying biological basis?

At the minute, there is simply not enough data to answer this definitively. While we are starting to tease apart these questions, it highlights the need for greater innovation within the recombinant protein supply chain to bring best practice and innovation from other areas to improve the robustness of the global supply chain and encourage great openness and scrutiny of fundamental biochemical quality early in process development.

Questions we should ask include: are we seeing heterogeneity in post-translational modifications, which is well documented in monoclonal antibody manufacturing? Can synthetic biology or protein engineering be used to optimize proteins and engineer out features contributing to this variation?

For now, and until we have answers, its a good idea to source proteins from reputable suppliers that have rigorous standards for batch quality testing and meticulously scrutinize all biochemical and bioactivity data provided.2.Cost of goods as a barrier to scaleTo bring innovative stem cell applications to market, pharma and biotech companies need to be able to seamlessly scale their cultures, meet regulatory requirements and achieve a sensible and sustainable process cost. Where recombinant proteins are needed in cell culture media, they are usually the greatest contributor to cost of goods.

Well-defined industry challenges catalyze change and the stem cell field is seeing renewed focus on much needed innovation in complex bioactive protein production to meet the needs for animal-free, highly reproducible proteins. Protein engineering technology, enhanced cell-based and cell-free expression systems, such as bacteria, yeast and even plants, coupled with improvements to downstream processing systems are just some of the latest innovations in this space. Previously, there have been concerns over the ability of simpler systems to form correctly folded and bioactive recombinant proteins. However, it is clear that many of these barriers can be overcome to produce highly pure growth factors and cytokines at scale.Others are striping back chemically-defined media protocols to determine the essential growth factors and cytokines needed for their cell type. For example, homebrews of key growth factors to reduce costs - Paul Burridge and his team at Northwestern University Feinberg School of Medicine have pioneered a cost-effective B8 chemically-defined media for weekend-free hiPSC culture at just 3% of the price of commercially available media. Now the challenge is to take the learnings from academic studies such as these and translate them into industrial processes.Meating the price of lab-grown steaksYou cannot discuss the cost of growth factors without mentioning the daunting step-change and barrier facing the fast-evolving cultured meat market. Here, highly optimized animal-free growth factor production systems will be required to provide the economies of scale needed to deliver kilogram-ton quantities at a fraction of the price in order to bring these lab-grown meat alternatives to consumers. After all, it just isnt viable for companies to be spending hundreds of dollars on each liter of culture media - instead, this needs to be reduced to ~$1/liter.3.Animal-free or ADCF? Now that is the questionDespite animal-free/animal-derived component free (ADCF) growth factors and cytokines becoming increasing important, there are no standard definitions for these terms across the industry, with many protein manufacturers supporting the sector by defining their own internal standards. For the clinical space, the United States Pharmacopeia and International Organization for Standardization have published a framework for classifying raw materials used in cell therapy manufactureinto four different tiers based on their risk. Under this classification, ancillary materials used in the manufacture of cell-based therapies and tissue-engineered products, such as recombinant growth factors and cytokines, are considered low risk so fall into tiers 1 and 2 with an ADCF level of manufacturing defined as all components, sub-components and consumables do not contain materials derived from animals.To support the wider sector, not just those at the transition to the clinic, clarity over definitions and transparency from manufacturers will help to define and overcome the challenges faced and allow the promise of stem-cell derived innovations to be delivered.

Article Authors:

Beata Blaszczyk, Senior Scientist, Qkine

Dr Catherine Elton, CEO and Founder, Qkine

Read more from the original source:
The Road To Scale: Challenges Facing the Implementation of Animal-Free Recombinant Proteins Into Stem Cell Supply Chains - Technology Networks

Posted in Stem Cell Therapy | Comments Off on The Road To Scale: Challenges Facing the Implementation of Animal-Free Recombinant Proteins Into Stem Cell Supply Chains – Technology Networks

Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH) – PRNewswire

Posted: August 26, 2020 at 8:00 pm

ATLANTA, Aug. 24, 2020 /PRNewswire/ -- Primary HLH is a family of devastating primary immune deficiencies with limited treatment options and no gene therapies under clinical testing. Expression Therapeutics has developed a promising and potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis (HLH) type 3 (FHL3). Untreated, FHL3 presents as a hyper-inflammatory state with multi-organ damage leading to premature death. Expression Therapeutics expects to rapidly progress candidates for other common forms of primary HLH as well.

"We are excited to announce this expansion of our gene and cell therapy pipeline beyond our lead stem cell lentiviral gene therapy candidate for hemophilia A that is entering Phase 1 clinical testing. Through ongoing research and development incorporating our core technology platforms, Expression Therapeutics has been able to rapidly generate promising therapeutic candidates for our HLH portfolio and several other critical disease areas with significant unmet clinical need," said Christopher Doering, Ph.D., Chief Scientific Officer of Expression Therapeutics.

Proof of concept for stem cell lentiviral gene therapy of FHL3 was demonstrated using primary patient cells and a genetic mouse model of FHL3. A key component in this success was the integration of one of Expression Therapeutics' core technology platforms that facilitates the rapid generation of transgenes with superior potency. Our lead candidate successfully restored exocytosis and cytolytic function to primary patient cells as well as a murine disease model strongly supporting the advancement of this pipeline product candidate.

"We believe there are three key aspects to FHL3 that make it a strong candidate for hematopoietic stem and progenitor cell (HSPC) lentiviral vector (LV) gene therapy. First, preclinical and clinical studies suggest that less than 20% genetically corrected cells are required to reverse most FHL3 disease symptoms. Second, because of the autologous nature of stem cell-based lentiviral gene therapy, the grave risk of graft vs host disease is eliminated. Third, with stem cell-based lentiviral gene therapy there will be no wait time to find a sufficiently human leukocyte antigen-matched donor," said Trent Spencer, Ph.D., President of Expression Therapeutics.

According to Deanna Fournier, Executive Director of the Histiocytosis Association, "We are very excited about the possibilities this work offers. Our HLH community, and the entire histiocytosis community, is very hopeful and excited about the future!"

Expression Therapeutics is a biotechnology company based in Atlanta and Cincinnati. The current therapeutic pipeline includes advanced gene therapies for hemophilia, neuroblastoma, T-cell leukemia/lymphoma, acute myeloid leukemia (AML), and primary immunodeficiencies such as hemophagocytic lymphohistiocytosis (HLH).

For inquiries, please contact:

Ashley WalshDirector of Corporate DevelopmentExpression Therapeutics 1860 Montreal RoadTucker, Georgia 30084[emailprotected]+1 312.637.2975www.expressiontherapeutics.com

SOURCE Expression Therapeutics

http://www.expressiontherapeutics.com

See the original post here:
Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH) - PRNewswire

Posted in Stem Cell Therapy | Comments Off on Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH) – PRNewswire

Animal Stem Cell Therapy Market Recent Study Including Growth Factors, Applications, Regional Analysis, and Forecast to 2027 – Scientect

Posted: August 26, 2020 at 8:00 pm

(Augest 2020) SMI published a business research report on Animal Stem Cell Therapy Market: Global Industry Analysis, Size, Share, Growth,Trends, and Forecasts 20202027. Research reportwith 110+ pages on market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

Key players are expected to enhance their marketing capabilities over the forecast period owing to certain market conditions. The report presents certain elements that will reflect whats and hows of such changes in the market. Further, the report studies various aspects of the global market such as upstream raw materials, downstream demand, and production value of leading players subject to market growth.

Download Free Sample Copy of this Report @ https://www.stratagemmarketinsights.com/sample/15082

Geographical segmentation of the Animal Stem Cell Therapy Market involves the regional outlook which further covers the United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and applications.

Animal Stem Cell Therapy Market: Competitive Landscape

Leading players operating in the global Animal Stem Cell Therapy market include Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel.

Scope of the Report:

The key features of the Animal Stem Cell Therapy Market report 2020-2027 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up of tables, charts, and figures that give our clients a clear picture of the Animal Stem Cell Therapy Market. The structure of the Animal Stem Cell Therapy Market by identifying its various segments and sub-segments to help to understand the report.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is the major reason for the expansion of this market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Is something restraining your companys growth in the Animal Stem Cell Therapy Market? Ask for the Free sample report here-https://www.stratagemmarketinsights.com/sample/15082

Important Data Available In This Report:

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms, and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus.

Customer Experience Analysis:

The study offers an in-depth assessment of various customers journeys pertinent to the market and its segments. It offers various customer impressions about products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

How will the report assist your business to grow?

Do You Have Any Query Or Specific Requirement? Ask Our Industry Expert @ https://www.stratagemmarketinsights.com/quiry/15082

Thanks a million for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest.

Related Blogs:Shubham

Here is the original post:
Animal Stem Cell Therapy Market Recent Study Including Growth Factors, Applications, Regional Analysis, and Forecast to 2027 - Scientect

Posted in Stem Cell Therapy | Comments Off on Animal Stem Cell Therapy Market Recent Study Including Growth Factors, Applications, Regional Analysis, and Forecast to 2027 – Scientect

Stem Cell Therapy Market to Show Incredible Growth by 2025 – Scientect

Posted: August 26, 2020 at 7:59 pm

The current report on Stem Cell Therapy Market covers a comprehensive analysis demonstrating actionable insights for clients. In addition, the report offers business insights that encourage them to take suitable decisions which are likely to leverage their business processes. Moreover, the report is a detailed study exhibiting current market trends with an overview of future market study.

Request Sample copy of this report at https://www.precisionbusinessinsights.com/request-sample?product_id=15608

Some of the players in the Stem Cell Therapy market include:

Cytori Therapeutics Inc. (U.S.), Fibrocell Science (U.S.), Cellartis AB (Cellectis) (France), BioTime, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), STEMCELL Technologies Inc. (Canada), Fujifilm Holdings Corporation (Japan), Vericel Corporation (Aastrom Bioscience) (U.S.), Brainstorm cell therapeutics (U.S.), and Osiris Therapeutics, Inc. (U.S.) to name a few.

PrecisionBusinessInsights has recently launched a latest report on Stem Cell Therapy Market for its clients. This report offers the clients with factual data validated by industry experts and business heads. The report highly involves chapter wise explanation for every aspect of the market wherein the drivers, trends, opportunities, leading and trending segments are discussed in detail with specific examples. Profiles of leading players are also discussed along with their business expansion strategies.

An overview of the Stem Cell Therapy Market report offers a comprehensive analysis for better reference to understand market competition and analysis throughout the forecast period. It also involves key players and their market performance and current developments. It helps you understand the technical jargons that offer ease and convenience to you in understanding the report contents.

Request Customization copy of this report at https://www.precisionbusinessinsights.com/request-customisation?product_id=15608

Geographical markets are covered separately within the report that includes a competitive analysis on their market performance in the base year as well as predictions for the forecast year. Extensive primary research is conducted to carry out leading information in order to understand the market condition and competition within a specified geography. Comparison between two or multiple geographical markets is carried out effectively to know where to invest in.

Key Features of the Report:

What is the Impact of Covid-19 Outbreak on the Stem Cell Therapy?

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

More here:
Stem Cell Therapy Market to Show Incredible Growth by 2025 - Scientect

Posted in Stem Cell Therapy | Comments Off on Stem Cell Therapy Market to Show Incredible Growth by 2025 – Scientect

GoBroad Healthcare Group Showcases Innovative Hematologic Treatment Capabilities at the China Precision Medicine Forum – PRNewswire

Posted: August 26, 2020 at 7:59 pm

40 experts delivered keynote speeches or participated in discussions during the online event, which attracted participants from more than 300 hospitals/institutes and over 40,000 views. Prof. John Gribben, Centre Lead of Haemato-Oncology at Barts Cancer Institute at Queen Mary, University of London, UK and the President of the European Hematology Association (EHA), gave a speech on Advances in Diagnosis and Treatment of Lymphoma in Europe; Prof. Dong Chen, Division of Hematopathology, Department of Laboratory Medicine and Pathology at Mayo Clinic, presented his insights on Integrated Hematopathology Reporting; Prof. Jun Zhu, Director of the Department of Internal Medicine at Beijing Cancer Hospital, who is also the Vice Chairman of GoBroad's Scientific Advisory Board, shares the Current Status and Prospects of the Lymphoma-related Investigational New Drug (IND) in China, etc.

Driven by strong innovation in both research and operation, GoBroad Healthcare Group has created a unique model for specialized treatments in hospitals since its inception in 2017.As of the end of July this year, the healthcare group has conducted over 600 cases of hematopoietic stem cell transplant, registered around 30 clinical trials of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and undertaken over 1,000 CAR-T treatments. The healthcare group has also published eight academic papers in key hematology journals, includingBloodandLeukemia.

GoBroad Healthcare Group offers advanced services and treatments for the entire range of specialties in hematologic malignancies. Its clinical programs include the discovery and treatment of lymphoma and leukemia in adults and children and a centre dedicated to hematologic and respiratory diseases. GoBroad Medical Institute of Hematology (Beijing Centre) has successfully undertook cutting-edge treatments such as a 23-second allogeneic hematopoietic cell transplant with a survival rate of 88.7%, higher than the global average. GoBroad Medical Institute of Hematology (Guangdong Centre) has adopted the TCR-T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant to largely reduce GVHD and increase the survival rate. For the first case around the world, the team successfully conducted hematopoietic cell transplant to treat a young patient suffering from Lysinuric Protein Intolerance (LPI) and Systemic Lupus Erythematosus (SLE).

"At the very beginning, we saw which clinical services were in urgent need. Innovation has propelled GoBroad Healthcare Group to new heights, attracting top talent around the world," said the Mr. Zhang, CEO of GoBroad. "As we develop our own competencies in research and clinical treatment in hematologic malignancies, we'd like to work with industry-leading experts and professionals across the globe to further develop our capabilities."

Powered by the expertise of Mayo Clinic and led by the Chief Physician at the Pathobiology Department of Peking University Health Science Center, GoBroad Healthcare Group has built a laboratory for integrated diagnostics to facilitate data-driven clinical decision-making and enhancement of patient services.

GoBroad values talent. At GoBroad Healthcare Group, experts can work on their research and clinical treatments freely, without administrative requirements. They also can work alongside a digitalized operations system; the healthcare group even rolled out digital products created for the specific clinical needs of healthcare professionals. In addition to attracting talent, GoBroad has also been committed to talent nurturing. Since the first day, the healthcare group has been partnering with top academic institutions such as Tongji University, Beijing University of Chinese Medicine and the Institute of Hematology & Blood Diseases Hospital at Tianjin in a range of educational programs.

About China Cancer Immunotherapy and Targeting Therapy Conference & GoBroad Annual Medical Conference

First launched in 2019, the event was joined by over 500 prominent medical experts across the globe to present the latest development, innovative insights in the field. Prof. Xiaodong Wang, member of the National Academy of Sciences, USA and director of China's National Institute Of Biological Sciences (NIBS), Prof. Mitchell S. Cairo of New York Medical College, Prof. J. Joseph Melenhorst of University of Pennsylvania and faculties from Mayo Clinic, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and City of Hope National Medical Centre are invited to give keynote speeches.

About GoBroad Healthcare Group

Invested by Hillhouse Capital, GoBroad Healthcare Group is dedicated to creating a medical service and technological innovation platform integrating pharmaceutical production and research, with a focus on blood diseases and tumours, among other medical fields. Its medical ecosystem covers the entire hospital supply chain. From clinical laboratories, a medical imaging facility, and big data centres to biotherapy research and treatment. Currently, the group has three homoeopathy R&D centres and five hospitals in Beijing, Shanghai and Guangdong, with a total of 800 beds and 88 hematopoietic stem cell transplant wards.

SOURCE GoBroad Healthcare Group

See the original post here:
GoBroad Healthcare Group Showcases Innovative Hematologic Treatment Capabilities at the China Precision Medicine Forum - PRNewswire

Posted in Stem Cell Therapy | Comments Off on GoBroad Healthcare Group Showcases Innovative Hematologic Treatment Capabilities at the China Precision Medicine Forum – PRNewswire

FDA Clears Jointechlabs’ MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications – PRNewswire

Posted: August 26, 2020 at 7:59 pm

SAN FRANCISCO, Aug. 26, 2020 /PRNewswire/ --Jointechlabs a leader in point-of-care regenerative medicine therapies today announced that the U.S. Food and Drug Administration (FDA) cleared the company's MiniTCfor point-of-care fat tissue processing designed to obtain microfat (or fat grafts), for multiple indications. Jointechlabs plans to focus on a range of therapeutic areas including medical aesthetics, plastic surgery, orthobiologics and wound healing.

"The FDA clearance of MiniTC represents an important step forward in the regenerative medicine market," said Nathan Katz, Jointechlabs' CEO. "The company's comprehensive and proprietary technology provides a variety of tissue reconstruction and regeneration options, enabling healthcare practitioners in medical centers, hospitals and clinics to provide safe, reliable and cost-effective cell enriched fat grafts at the point-of-care."

MiniTC is a disposable, closed loop medical device that can be used in the clinic setting, with no change in infrastructure, eliminating the need for manual processing of fat tissue in the lab. Also, the device is less costly,cumbersome and labor intensive compared to what currently exists. MiniTC's performance has been validated in vitro and in vivo, including an observational orthopedic study in Israel and the UAE, involving 47 patients with 92% reporting functional improvement and no complications. Additionally, it was validated in clinical studies with lymphoedema patients as well as in the areas of facial aesthetics, hair regrowth and wound care.

"Jointechlabs' MiniTC device is easy to use and effective," said Joseph Purita, M.D., orthopedic surgeon and director of the Institute of Regenerative Medicine in Boca Raton, Florida."It is encouraging to see the continuing development of new technology for regenerative medicine that is compliant with FDA guidelines."

Microfat IsolationMiniTC allows for processing of adipose (fat) tissue without exposure to the external environment. The final product of the processing is a fine washed fractured fat tissue known as fat graft or microfat. When implanted by injection, the essential effect can be attributed to the preservation of the integrity of fat tissue and the stromal cells within its natural niche. Together it constitutes structural factors that trigger the reconstruction, regeneration and healing of connective tissues.It's a gentle process that uses an individual's own fat tissue tocushion and support areas of injury or damage as the body heals itself.

Pipeline ProductsJointechlabs has an extensive development program. In addition to MiniTC, the company's Mini-Stem a patented, disposable, closed loop medical device is pending approval in Europe (and under investigation in other countries) for isolation of stem cell fraction (SVF) from fat. Mini-Stem will enable doctors to provide safe, reliable, cost-effective non-surgical stem cell treatments at the point-of-care. Mini-Stem will serve as a platform for cell therapies and is well poised to target the developing regenerative medicine market, unlike any of the current devices.Additionally, Jointechlabs is developing proprietary stem cell-scaffold product as a biologic therapy for osteoarthritis, for approval under the FDA's fast-track program. A portion of the pre-clinical study for JTL-T-01 is funded by NIH's small business grant (SBIR grant) in collaboration with Rush University.

Headquartered in San Francisco, Jointechlabs is recognized as an experienced and respected emerging world leader in point-of-care regenerative medicine therapies. With its devices and technology, Jointechlabs enables healthcare practitioners to provide safe, reliable, cost-effective non-surgical regenerative medicine treatments at the point-of-care.For more information, please visit: http://jointechlabs.com/.

Media Contact:Betsy Levy | Phone: (415) 377-3112 | Email: [emailprotected]

SOURCE Jointechlabs

Redefining Adipose Technology

Here is the original post:
FDA Clears Jointechlabs' MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications - PRNewswire

Posted in Stem Cell Therapy | Comments Off on FDA Clears Jointechlabs’ MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications – PRNewswire

FINNCAP’S LIFE SCIENCES REPORT INDICATES CELL AND GENE THERAPY SECTOR IS DRIVING THE NEXT WAVE OF INNOVATION IN PHARMA – PharmiWeb.com

Posted: August 26, 2020 at 7:59 pm

Breakthrough in delivery for cell and gene therapy products has led to a wave of M&A activity as big pharma aims not to miss out on the future of medicine

AIM healthcare index at the centre of innovation, has risen 6% YTD compared with the AIM all share, which has declined 7%

finnLife 50 index has also risen 6% in 2020 led by gains in Synairgen (+2,930%), Avacta (+654%), Omega Diagnostics (+322%) and Tiziana Life Sciences (+283%)

London 25 August 2020 Healthcare companies employing and developing cell and gene therapy (C>) are driving the next wave of innovation in the pharmaceutical industry, leading to increased M&A activity as big pharma aims not to miss out on the future of medicine. The AIM healthcare index has been at the centre of this innovation, rising 6% YTD compared with the AIM all share, which has declined 7%.

These are the findings of finnCaps new quarterly Life Sciences sector report, Rude Health.

Rather than just treating a disease and its symptoms, C> can target the underlying cause of a disease, with long-term benefits and curative potential. C> is now being realised on an applicable level, with many products already approved and the FDA expects to approve 10-20 products a year by 2025.

The financials of the sector are reflective of this rapid progress. In 2018, the market value of C> was $536 million - $1.07 billion; but by 2026 it is set to have a valuation of up to$35.4 billion. Given the high proportion of start-ups in the sector, M&A activity is on the rise, as evidenced by the $3 billion Astellas spent in January 2020 to acquire Audentes Therapeutics, specialists in genetics medicines.

In 2014/2015, M&A activity in the sector was $5 billion; by 2018/2019 it had surged 880% to $49 billion. Much of this is driven by big pharma firms not wanting to fall behind their smaller, more versatile competition, as they did with monoclonal antibody technology. Consequently, they have engaged with M&A to speed up and enhance their own R&D efforts.

The report notes that innovators in C> will be well placed to take part in the land grab that will follow as a result of continued advancements in the sector, and highlights now as a good time for investors and pharmaceutical companies to become involved as the sector is rapidly maturing past its high potential research and development stage with an established pipeline of therapies already being developed.

Some of the key reasons why the report considers the C> sector to be an attractive one for investment are:

Pharmas next wave of innovation. C>s can be potentially curative treatment options as they usually target the underlying cause of disease. In the long term, these therapies could become the backbone of treatment regimens, and solutions to various unmet needs.

Deals. Big Pharma had to play catch-up with monoclonal antibody technology and seems determined not to make the same mistake with C>, as reflected in the high deal activity and high deal values seen within this space.

Sector maturation. Advances in the sector mean that the C> sector is beginning to mature beyond the R&D stage and into commercialisation, with some products already approved, and with a very large future pipeline of therapies.

Revenue.Therapies in this space can command high prices, allowing for high revenue generation, even from rare diseases and limited patient populations.

Despite its vital role in the future of medicine, C> also comes with challenges. The report highlights that the manufacture of C>s is difficult given they are, by definition, personalised for the patient. This means they cannot be batch produced for distribution to multiple patients as more traditional medicines can. For example, Zolgensma, which treats those with motor neurone disease, is priced at $2.1 (1.6) million per therapy, making it the most expensive drug treatment ever.

The report also notes how the payment process for C> requires a reworking of reimbursement systems not used to outlaying so much money up front for a treatment with long-term benefits/curative potential versus continuous, and lower payments for ongoing medicine treatment.

The technologies the report shines a spotlight include CAR-T therapy, stem cell therapy, CRISPR, RNA therapies, among various others.

Arshad Ahad, Research Analyst, Life Sciences, at finnCap, commented:Few technologies in the life sciences sector hold as much promise as Cell and Gene Therapy, with its ability to provide long-term benefits and curative potential. These technologies have been seen as the future of medicine for many years, and now we are closer than ever to that future becoming a reality. If Cell and Gene therapy does become the backbone of treatment regimes in the future, similar to the rise of monoclonal antibodies, then the companies involved are developing expertise in a critical part of the life sciences industry, which should confer a significant competitive advantage as the sector matures further. Now is therefore a good time to invest in the future.

Original post:
FINNCAP'S LIFE SCIENCES REPORT INDICATES CELL AND GENE THERAPY SECTOR IS DRIVING THE NEXT WAVE OF INNOVATION IN PHARMA - PharmiWeb.com

Posted in Stem Cell Therapy | Comments Off on FINNCAP’S LIFE SCIENCES REPORT INDICATES CELL AND GENE THERAPY SECTOR IS DRIVING THE NEXT WAVE OF INNOVATION IN PHARMA – PharmiWeb.com

Page 916«..1020..915916917918..930940..»